Susquehanna International Group, LLP Oncternal Therapeutics, Inc. Transaction History

Susquehanna International Group, LLP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$0.29 - $0.48 $1,065 - $1,763	3,673 Added 19.62%	22,393 $6,000
Q2 2023 Aug 11, 2023	SELL	$0.28 - $0.79 $30,022 - $84,705	-107,222 Reduced 85.14%	18,720 $6,000
Q1 2023 May 16, 2023	BUY	$0.63 - $1.3 $79,343 - $163,724	125,942 New	125,942 $99,000
Q3 2022 Nov 14, 2022	BUY	$0.83 - $17.8 $14,734 - $316,003	17,753 Added 49.65%	53,506 $48,000
Q2 2022 Aug 15, 2022	BUY	$0.7 - $1.56 $15,721 - $35,036	22,459 Added 168.94%	35,753 $40,000
Q1 2022 May 16, 2022	SELL	$1.37 - $2.43 $74,185 - $131,584	-54,150 Reduced 80.29%	13,294 $18,000
Q4 2021 Feb 14, 2022	SELL	$2.27 - $4.39 $184,530 - $356,867	-81,291 Reduced 54.65%	67,444 $153,000
Q3 2021 Nov 15, 2021	SELL	$3.37 - $4.76 $251,361 - $355,038	-74,588 Reduced 33.4%	148,735 $620,000
Q2 2021 Aug 11, 2021	SELL	$4.75 - $9.39 $1.32 Million - $2.61 Million	-278,285 Reduced 55.48%	223,323 $1.06 Million
Q1 2021 May 17, 2021	BUY	$4.59 - $9.04 $2.18 Million - $4.29 Million	474,576 Added 1755.61%	501,608 $4.17 Million
Q4 2020 Feb 16, 2021	BUY	$1.51 - $6.3 $40,818 - $170,301	27,032 New	27,032 $132,000

362K

Ticker ONCT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,517,200
Market Cap $29.4M
Description
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a smal...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.